Sanofi successfully prices EUR 1.5 billion of bond issue Paris, March 5, 2025. Sanofi announces that it has successfully priced its offering of ...
Four years after Sanofi shelled out $125 million for global rights to Biond Biologic | The company is handing back the tumor ...
South Africa's competition watchdog is investigating drugmakers Novo Nordisk and Sanofi over possible anti-competitive ...
The last few years have been tough for the insulin market, with recent policies and high-level pressure forcing companies to ...
Berenberg analyst Luisa Hector raised the firm’s price target on Sanofi (SNY) to EUR 120 from EUR 115 and keeps a Buy rating on the ...
Novavax on Thursday posted a narrower fourth-quarter loss and said it expects its licensing deal with French drugmaker Sanofi ...
Tolebrutinib is more effective in reducing the risk of disability progression in MS patients with paramagnetic rim lesions, ...
Detailed results presented at a medical congress help reinforce analyst expectations the drug, called duvakitug, will be ...
Novo Nordisk A/S and Sanofi are facing an investigation in South Africa over concerns about potential anti-competitive practices in the human insulin pen market.
Posters presented at the Association of Cancer Care Centers opening session covered initiatives to boost clinical trial ...
10d
GlobalData on MSNSanofi and Teva report new outcomes from Phase IIb trial of duvakitugSanofi and Teva Pharmaceuticals have reported new outcomes from the randomised Phase IIb RELIEVE UCCD trial of human ...
Kuehne+Nagel supports Sanofi in multiple countries worldwide, including Hungary, the UK, and the UAE, by providing customised ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results